Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vebicorvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vebicorvir SCHEMBL29485072 | 1.00 | MAPT (0.40) | MAPTPOLBPKMALDH1A1HPGD | |
| Vebicorvir SCHEMBL21250344 | 1.00 | MAPT (0.40) | MAPTPOLBPKMALDH1A1HPGD | |
| SCHEMBL22746372 | 0.91 | DRD2 (0.37) | MAPTPOLBPKMHPGDSMN1; SMN2 | |
| SCHEMBL18667100 | 0.91 | ALDH1A1 (0.42) | MAPTPOLBPKMALDH1A1HPGD | |
| SCHEMBL21291402 | 0.90 | ROCK2 (0.38) | POLBPKMKMT2A | |
| SCHEMBL18667097 | 0.88 | L3MBTL1 (0.35) | MAPTPOLBPKMALDH1A1HPGD | |
| SCHEMBL19984571 | 0.88 | POLB (0.35) | POLBPKMKMT2ADRD2 | |
| SCHEMBL17080158 | 0.87 | MAPT (0.42) | MAPTPOLBPKMALDH1A1HPGD | |
| SCHEMBL29358192 | 0.87 | MAPT (0.44) | MAPTPOLBPKMALDH1A1HPGD | |
| SCHEMBL18667173 | 0.87 | MAPT (0.44) | MAPTPOLBPKMALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654973-A1 | HEPATITIS B COMBINATION THERAPIES | Aligos Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| EP-4493694-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119032175-A | Modified spacer oligomers and methods of use thereof | 阿利戈斯治疗公司 | 2024-11-26 | — | — | CN | claimed |
| WO-2024158904-A1 | HEPATITIS B COMBINATION THERAPIES | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | claimed |
| WO-2023177808-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | claimed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | claimed |
| US-20230123601-A1 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | HOFFMANN-LA ROCHE INC. | 2023-04-20 | — | — | US | claimed |
| US-20230044958-A1 | METHOD OF TREATING VIRUS INFECTION USING A TLR7 AGONIST | HOFFMANN-LA ROCHE INC. (US) | 2023-02-09 | — | — | US | claimed |
| EP-4121533-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| CN-115485384-A | Modified short interfering nucleic acid (siNA) molecules and uses thereof | 阿利戈斯治疗公司 | 2022-12-16 | — | — | CN | claimed |
| US-20220364096-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | claimed |
| EP-4081216-A1 | METHOD OF TREATING VIRUS INFECTION USING A TLR7 AGONIST | F. Hoffmann-La Roche AG (CH) | 2022-11-02 | — | — | EP | claimed |
| EP-4081217-A1 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | F. Hoffmann-La Roche AG (CH) | 2022-11-02 | — | — | EP | claimed |
| EP-4073071-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | Gannex Pharma Co., Ltd. (CN) | 2022-10-19 | — | — | EP | claimed |
| CN-115103674-A | Methods of treating viral infections using TLR7 agonists | 豪夫迈·罗氏有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-114828852-A | HBV-targeted antiviral and/or immunomodulatory agent pharmaceutical combinations for the treatment of HBV | 豪夫迈·罗氏有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-112891348-B | Use of phenyl isoxazolyl methylene-naphthalene-ether derivatives and pharmaceutical compositions | 甘莱制药有限公司 | 2022-06-28 | — | — | CN | claimed |
| CN-114469945-A | Use of fatty acid synthase inhibitors and pharmaceutical compositions | 歌礼生物科技（杭州）有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3976056-A2 | MODIFIED GAPMER OLIGONUCLEOTIDES AND METHODS OF USE | Aligos Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| EP-4747381-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PD-L1 | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731254-A2 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | Brii Biosciences, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260028603-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260002944-A1 | BIOMARKERS OF FIBROSIS AND USES THEREFOR | UNIV GRIFFITH (AU) | 2026-01-01 | — | — | US | disclosed |
| US-20260002157-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4667477-A2 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4654973-A1 | HEPATITIS B COMBINATION THERAPIES | Aligos Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | SOPONPONG JAKAPUN (TH) | 2025-11-27 | — | — | US | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250346877-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250345389-A1 | COMBINATION THERAPIES | GILEAD SCIENCES INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250345390-A1 | COMBINATION THERAPIES | GILEAD SCIENCES INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12454691-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4626879-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250304542-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4192474-B1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612294-A2 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12410418-B2 | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome | PRECISION BIOSCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4600247-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12364751-B2 | HBV vaccines and methods treating HBV | GILEAD SCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-3781556-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4567109-A2 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | Precision Biosciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12318403-B2 | 2′3′-cyclic dinucleotides and prodrugs thereof | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2025-06-03 | — | — | US | disclosed |
| US-20250171757-A1 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025101962-A1 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-114245807-B | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250127886-A1 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | BRII BIOSCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| EP-4533099-A1 | BIOMARKERS OF FIBROSIS AND USES THEREFOR | Griffith University (AU) | 2025-04-09 | — | — | EP | disclosed |
| CN-119770638-A | HBV vaccine and method of treating HBV | 吉利德科学公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12269812-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-111954675-B | 3' -Cyclic dinucleotides | 捷克共和国有机化学与生物化学研究所 | 2025-04-01 | — | — | CN | disclosed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-113574063-B | 3' -Cyclic dinucleotides and prodrugs thereof | 捷克共和国有机化学与生物化学研究所 | 2025-03-18 | — | — | CN | disclosed |
| CN-113543851-B | 2'3' -Cyclic dinucleotides and prodrugs thereof | 捷克共和国有机化学与生物化学研究所 | 2025-03-18 | — | — | CN | disclosed |
| CN-113767098-B | Solid forms of Toll-like receptor modulators | 吉利德科学公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-113906023-B | Solid forms of TOLL-like receptor modulators | 吉利德科学公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-111954676-B | 2'3' -Cyclic dinucleotides | 捷克共和国有机化学与生物化学研究所 | 2025-01-24 | — | — | CN | disclosed |
| WO-2025016444-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PD-L1 | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-23 | — | — | WO | disclosed |
| EP-4069729-B1 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PREC BIOSCIENCES INC (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-4493694-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2025015063-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-119212987-A | Methods and compositions for targeting PD-L1 | 安力高医药股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024263918-A2 | ASSESSMENT AND TREATMENT OF CHRONIC HEPATITIS B | BRII BIOSCIENCES, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-114555799-B | HBV vaccine and method of treating HBV | 吉利德科学公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-119032175-A | Modified spacer oligomers and methods of use thereof | 阿利戈斯治疗公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240376100-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | Redona Therapeutics, Inc. | 2024-11-14 | — | — | US | disclosed |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4458975-A2 | HBV VACCINES AND METHODS TREATING HBV | Gilead Sciences, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4458416-A2 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | Gilead Sciences, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4230209-B1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | CHA VACCINE RES INSTITUTE CO LTD (KR) | 2024-10-30 | — | — | EP | disclosed |
| US-12129469-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-118846028-A | HBV vaccine and method of treating HBV | 吉利德科学公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024216341-A1 | NUCLEIC ACIDS TARGETING HEPATITIS B VIRUS (HBV) TRANSCRIPTS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2024-10-24 | — | — | WO | disclosed |
| EP-4448512-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-12110305-B2 | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240325409-A1 | Fused Heterotetracyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| WO-2024206663-A1 | REACTIVE CAPSID PROTEIN ASSOCIATED MOLECULES | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-4037708-B1 | HBV VACCINES AND METHODS TREATING HBV | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-3956328-B1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024182271-A1 | FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-112955435-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240269142-A1 | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS | GILEAD SCIENCES, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240269235-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| WO-2024158904-A1 | HEPATITIS B COMBINATION THERAPIES | ALIGOS THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024155717-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-4399206-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | Redona Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-4399217-A2 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118221646-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118201914-A | 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors | 雷多纳治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118201942-A | Modified short interfering nucleic acid (siNA) molecules and uses thereof | 阿利戈斯治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11999733-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-118084940-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4371987-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | Gilead Sciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359389-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359413-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4359411-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3956329-B9 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117843811-A | HBV vaccine and method of treating HBV | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11939581-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| CN-112399874-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4337202-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337223-A1 | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV SIRNA THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11932634-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240066117-A1 | HBV VACCINES AND METHODS TREATING HBV | GILEAD SCIENCES, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11897878-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11896648-B2 | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240035011-A1 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| CN-117396478-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-3956329-B1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117377671-A | Diacylglycerol kinase modulating compounds | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117279649-A | Combinations of TLR8 modulating compounds and anti-HBV siRNA therapeutics | 吉利德科学公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230405112-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | CHA VACCINE RESEARCH INSTITUTE CO., LTD (KR) | 2023-12-21 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230383296-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023225723-A1 | BIOMARKERS OF FIBROSIS AND USES THEREFOR | GRIFFITH UNIVERSITY (AU) | 2023-11-30 | — | — | WO | disclosed |
| CN-117105933-A | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364092-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-112969505-B | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11788077-B2 | Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome | PRECISION BIOSCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-112041311-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-111566120-B | 3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein | 捷克共和国有机化学与生物化学研究所 | 2023-09-29 | — | — | CN | disclosed |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| WO-2023177808-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760755-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-111511754-B | 2'3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein | 捷克共和国有机化学与生物化学研究所 | 2023-09-12 | — | — | CN | disclosed |
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234030-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4232463-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738019-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230209-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | Cha Vaccine Research Institute Co., Ltd (KR) | 2023-08-23 | — | — | EP | disclosed |
| US-11730808-B2 | HBV vaccines and methods treating HBV | GILEAD SCIENCES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3820572-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227302-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11718637-B2 | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| CN-116529258-A | Interleukin-2-Fc fusion proteins and methods of use | 吉利德科学公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2019195181-A9 | ANTIBODIES AND FRAGMENTS THEREOF THAT BIND HEPATITIS B VIRUS PROTEIN X | GILEAD SCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023114365-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| EP-4192474-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4189089-A1 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | Aligos Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-116209663-A | Methods and compositions for targeting PD-L1 | 安力高医药股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116196434-A | Antibody-drug conjugate, preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4185569-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116194144-A | Prodrugs of phosphoramide nucleotide analogs and pharmaceutical uses thereof | 吉利德科学公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-111788204-B | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116057068-A | Optimized engineered meganucleases with specificity for recognition sequences in hepatitis b virus genomes | 精密生物科学公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230127898-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
| US-20230123601-A1 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | HOFFMANN-LA ROCHE INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3752501-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20230114007-A1 | HBV VACCINES AND METHODS TREATING HBV | GILEAD SCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230116253-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230109134-A1 | PYRIDAZINONE OR PYRIDAZINE COMPOUND AND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | SHANGHAI ZELGEN PHARMA.TECH CO., LTD. (CN) | 2023-04-06 | — | — | US | disclosed |
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. | 2023-04-06 | — | — | US | disclosed |
| EP-4153567-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| CN-115835907-A | Methods and compositions for targeting PD-L1 | 安力高医药股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2023039005-A2 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| WO-2023039089-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | TWENTYEIGHT-SEVEN, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| US-11605460-B2 | Multi-targeted fibrosis tests | CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS (FR) | 2023-03-14 | — | — | US | disclosed |
| US-20230075366-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230065527-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060354-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060004-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | US | disclosed |
| US-11583531-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230046340-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11578117-B2 | Antibodies and fragments thereof that bind hepatitis B virus protein X | GILEAD SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230044958-A1 | METHOD OF TREATING VIRUS INFECTION USING A TLR7 AGONIST | HOFFMANN-LA ROCHE INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230031465-A1 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | PRECISION BIOSCIENCES, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-20230031213-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| EP-4121437-A1 | PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4121533-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES AND USES THEREOF | Aligos Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11555029-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20230008368-A1 | IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-11549110-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4110922-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | Aligos Therapeutics, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022271677-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271650-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271659-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022266236-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-115485384-A | Modified short interfering nucleic acid (siNA) molecules and uses thereof | 阿利戈斯治疗公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022251594-A1 | PHARMACOKINETICS AND DOSE-RELATED IMPROVMENTS IN SUBJECTS TREATED WITH PHOSPHORAMIDATE CLEVUDINE PRODRUGS | Antios Therapeutics, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| US-20220364096-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2022241134-A1 | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220363708-A1 | PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2022-11-17 | — | — | US | disclosed |
| US-11497808-B2 | HBV vaccines and methods treating HBV | GILEAD SCIENCES, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| EP-4081216-A1 | METHOD OF TREATING VIRUS INFECTION USING A TLR7 AGONIST | F. Hoffmann-La Roche AG (CH) | 2022-11-02 | — | — | EP | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| EP-4081217-A1 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | F. Hoffmann-La Roche AG (CH) | 2022-11-02 | — | — | EP | disclosed |
| EP-4073071-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | Gannex Pharma Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| US-11472808-B2 | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4069729-A1 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | Precision BioSciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11466274-B2 | Modified gapmer oligonucleotides and methods of use | ALIGOS THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-115176009-A | Methods and compositions for targeting PD-L1 | 安力高医药股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-11453681-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-115103674-A | Methods of treating viral infections using TLR7 agonists | 豪夫迈·罗氏有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220296619-A1 | PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-4059938-A1 | IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| EP-4050008-A1 | PYRIDAZINONE OR PYRIDAZINE COMPOUND AND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2022-08-31 | — | — | EP | disclosed |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220257619-A1 | LONG-ACTING FORMULATIONS OF TENOFOVIR ALAFENAMIDE | DURECT CORPORATION | 2022-08-18 | — | — | US | disclosed |
| EP-4037708-A1 | HBV VACCINES AND METHODS TREATING HBV | GILEAD SCIENCES, INC. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114828852-A | HBV-targeted antiviral and/or immunomodulatory agent pharmaceutical combinations for the treatment of HBV | 豪夫迈·罗氏有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11396509-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20220213091-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| CN-112891348-B | Use of phenyl isoxazolyl methylene-naphthalene-ether derivatives and pharmaceutical compositions | 甘莱制药有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220177888-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| CN-114555799-A | HBV vaccines and methods for treating HBV | 吉利德科学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022108094-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | 주식회사 차백신연구소 | 2022-05-27 | — | — | WO | disclosed |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| WO-2022026387-A9 | HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-19 | — | — | US | disclosed |
| CN-114469945-A | Use of fatty acid synthase inhibitors and pharmaceutical compositions | 歌礼生物科技（杭州）有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-05-12 | — | — | US | disclosed |
| EP-3990476-A1 | FLT3L-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220125884-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022087149-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| EP-3976056-A2 | MODIFIED GAPMER OLIGONUCLEOTIDES AND METHODS OF USE | Aligos Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11292812-B2 | 3′3′-cyclic dinucleotides | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2022-04-05 | — | — | US | disclosed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | MAPT 3509/4885POLB 782/4885PKM 946/4885 |
| US-11377450-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | MAPT 4614/4885POLB 368/4885PKM 2159/4885 |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | MAPT 3509/4885POLB 782/4885PKM 946/4885 |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | VIM, CYP3A7, HAVCR2 | MAPT 499/4885POLB 1280/4885PKM 300/4885 |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | MAPT 4391/4885POLB 233/4885PKM 3935/4885 |
| US-20230107941-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | MAPT 1087/4885POLB 996/4885PKM 4499/4885 |
| US-20240277706-A1 | METHODS AND COMPOSTITIONS FOR TARGETING PD-L1 | CD274, PDCD1, PDCD1LG2 | MAPT 2186/4885POLB 567/4885PKM 1926/4885 |
| US-12269812-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | MAPT 3557/4885POLB 486/4885PKM 1743/4885 |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | MAPT 4614/4885POLB 368/4885PKM 2159/4885 |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885POLB 3027/4885PKM 1463/4885 |
| US-20250345390-A1 | COMBINATION THERAPIES | HDGF, GLP1R, VIP | MAPT 3938/4885POLB 3341/4885PKM 2470/4885 |
| US-20220363708-A1 | PRODRUGS OF 4'-C-SUBSTITUTED-2-HALO-2'-DEOXYADENOSINE NUCLEOSIDES AND METHODS OF MAKING AND USING THE SAME | DCTD, MTAP, ADA | MAPT 4508/4885POLB 385/4885PKM 4077/4885 |
| US-11555029-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | MAPT 3524/4885POLB 382/4885PKM 1012/4885 |
| US-20230060004-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4483/4885POLB 3212/4885PKM 827/4885 |
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | MAPT 3509/4885POLB 782/4885PKM 946/4885 |
| US-20230212155-A1 | PD-1/PD-L1 INHIBITORS | PDCD1, CD274, PDCD1LG2 | MAPT 3524/4885POLB 382/4885PKM 1012/4885 |
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | RNGTT, PHAX, HAVCR2 | MAPT 4184/4885POLB 56/4885PKM 3130/4885 |
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | SNRPA, SNRPA1, NSUN2 | MAPT 3616/4885POLB 57/4885PKM 3883/4885 |
| US-20260002157-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | SRRT, SLIRP, FBL | MAPT 3382/4885POLB 317/4885PKM 1969/4885 |
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | MAPT 3425/4885POLB 38/4885PKM 3179/4885 |
| US-20220364096-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | MAPT 3425/4885POLB 38/4885PKM 3179/4885 |
| US-11549110-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | NSUN2, SNRPA, SNRPF | MAPT 3425/4885POLB 38/4885PKM 3179/4885 |
| US-20220177888-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | MAPT 3425/4885POLB 38/4885PKM 3179/4885 |
| US-20230192713-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | MAPT 2382/4885POLB 1642/4885PKM 2707/4885 |
| US-20230116253-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4483/4885POLB 3212/4885PKM 827/4885 |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | MAPT 4656/4885POLB 1017/4885PKM 3996/4885 |
| US-20230008368-A1 | IMIDAZOQUINOLINE SUBSTITUTED PHOSPHORIC ESTER AGONIST, AND PREPARATION THEREFOR AND APPLICATION THEREOF | TLR4, TLR7, TLR1 | MAPT 4734/4885POLB 3825/4885PKM 2658/4885 |
| US-20230405112-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT | LIPC, VIP, IL17A | MAPT 4661/4885POLB 98/4885PKM 3234/4885 |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4206/4885POLB 3027/4885PKM 1463/4885 |
| US-11760755-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | MAPT 4468/4885POLB 152/4885PKM 3259/4885 |
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | MAPT 4447/4885POLB 291/4885PKM 2198/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | MAPT 3713/4885POLB 16/4885PKM 641/4885 |
| US-11453681-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | MAPT 4296/4885POLB 3055/4885PKM 692/4885 |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | STING1, MAVS, CGAS | MAPT 4655/4885POLB 1062/4885PKM 4098/4885 |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | MAPT 3713/4885POLB 16/4885PKM 641/4885 |
| US-11472808-B2 | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents | CCNC, HCCS, CDKN1A | MAPT 4111/4885POLB 26/4885PKM 1996/4885 |
| US-20220143061-A1 | 3'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, IRF3 | MAPT 4569/4885POLB 182/4885PKM 2490/4885 |
| US-20230123601-A1 | PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS TARGETING HBV AND/OR AN IMMUNE MODULATOR FOR TREATMENT OF HBV | HAVCR2, IRF3, IFNG | MAPT 4124/4885POLB 1429/4885PKM 3295/4885 |
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | MAPT 2382/4885POLB 1642/4885PKM 2707/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | MAPT 4206/4885POLB 3027/4885PKM 1463/4885 |
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | HAVCR2, HMBS, HDGF | MAPT 2991/4885POLB 130/4885PKM 3726/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | MAPT 4312/4885POLB 1884/4885PKM 3453/4885 |
| US-20220152078-A1 | 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF | STING1, CGAS, NT5C2 | MAPT 4500/4885POLB 195/4885PKM 2661/4885 |
| US-20230109134-A1 | PYRIDAZINONE OR PYRIDAZINE COMPOUND AND DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | TSHR, THRB, THRA | MAPT 468/4885POLB 2666/4885PKM 451/4885 |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | MAPT 3524/4885POLB 382/4885PKM 1012/4885 |
| US-12454691-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | SNRPA, SNRPA1, NSUN2 | MAPT 3616/4885POLB 57/4885PKM 3883/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | MAPT 2382/4885POLB 1642/4885PKM 2707/4885 |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | MAPT 4296/4885POLB 3055/4885PKM 692/4885 |
| US-20230060354-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAPT 4483/4885POLB 3212/4885PKM 827/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | MAPT 3425/4885POLB 38/4885PKM 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.